Skip to main content
Contact Us
Subscribe
E-Edition
86°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Belite Bio, Inc
Belite Bio to Present at the JonesHealthcare Seaside Summit
July 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
June 12, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
May 14, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
May 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
May 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 01, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces $25 Million Registered Direct Offering
April 25, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
March 22, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
March 04, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
November 07, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
November 06, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
October 27, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
August 08, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
August 04, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
July 27, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
July 24, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
May 10, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
May 10, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.